159 related articles for article (PubMed ID: 23411688)
1. Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.
Teramoto K; Ohshio Y; Fujita T; Hanaoka J; Kontani K
J Cancer Res Clin Oncol; 2013 May; 139(5):861-70. PubMed ID: 23411688
[TBL] [Abstract][Full Text] [Related]
2. Enhanced immune response induced by P5 HER2/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine.
Gholizadeh Z; Tavakkol-Afshari J; Nikpoor AR; Jalali SA; Jaafari MR
J Cell Mol Med; 2018 Jan; 22(1):558-567. PubMed ID: 28944998
[TBL] [Abstract][Full Text] [Related]
3. Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA.
Teramoto K; Kontani K; Fujita T; Ozaki Y; Sawai S; Tezuka N; Fujino S; Itoh Y; Taguchi O; Kannagi R; Ogasawara K
Cancer Immunol Immunother; 2007 Mar; 56(3):331-42. PubMed ID: 16896967
[TBL] [Abstract][Full Text] [Related]
4. Generation of tumor cell lysate-loaded dendritic cells preprogrammed for IL-12 production and augmented T cell response.
Vegh Z; Mazumder A
Cancer Immunol Immunother; 2003 Feb; 52(2):67-79. PubMed ID: 12594570
[TBL] [Abstract][Full Text] [Related]
5. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.
Galea-Lauri J; Darling D; Mufti G; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2002 Aug; 51(6):299-310. PubMed ID: 12111118
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma.
Pulaski BA; Clements VK; Pipeling MR; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2000 Apr; 49(1):34-45. PubMed ID: 10782864
[TBL] [Abstract][Full Text] [Related]
7. Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity.
Wells JW; Cowled CJ; Darling D; Guinn BA; Farzaneh F; Noble A; Galea-Lauri J
Cancer Immunol Immunother; 2007 Dec; 56(12):1861-73. PubMed ID: 17487489
[TBL] [Abstract][Full Text] [Related]
8. MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.
Poli C; Raffin C; Dojcinovic D; Luescher I; Ayyoub M; Valmori D
Haematologica; 2013 Feb; 98(2):316-22. PubMed ID: 22875619
[TBL] [Abstract][Full Text] [Related]
9. Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.
Fujiki F; Tsuboi A; Morimoto S; Hashimoto N; Inatome M; Nakajima H; Nakata J; Nishida S; Hasegawa K; Hosen N; Oka Y; Oji Y; Sogo S; Sugiyama H
Cancer Immunol Immunother; 2021 Jan; 70(1):253-263. PubMed ID: 32696072
[TBL] [Abstract][Full Text] [Related]
10. The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses.
Durán-Aniotz C; Segal G; Salazar L; Pereda C; Falcón C; Tempio F; Aguilera R; González R; Pérez C; Tittarelli A; Catalán D; Nervi B; Larrondo M; Salazar-Onfray F; López MN
Cancer Immunol Immunother; 2013 Apr; 62(4):761-72. PubMed ID: 23242374
[TBL] [Abstract][Full Text] [Related]
11. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer.
Gillogly ME; Kallinteris NL; Xu M; Gulfo JV; Humphreys RE; Murray JL
Cancer Immunol Immunother; 2004 Jun; 53(6):490-6. PubMed ID: 14740174
[TBL] [Abstract][Full Text] [Related]
12. Direct Loading of iTEP-Delivered CTL Epitope onto MHC Class I Complexes on the Dendritic Cell Surface.
Dong S; Wang P; Zhao P; Chen M
Mol Pharm; 2017 Oct; 14(10):3312-3321. PubMed ID: 28789525
[TBL] [Abstract][Full Text] [Related]
13. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
Knutson KL; Disis ML
Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
[TBL] [Abstract][Full Text] [Related]
14. Characterization of human CD4 helper T cell responses against Aurora kinase A.
Kobayashi H; Azumi M; Hayashi S; Sato K; Aoki N; Kimura S; Kakizaki H; Nagato T; Harabuchi Y; Tateno M; Celis E
Cancer Immunol Immunother; 2010 Jul; 59(7):1029-39. PubMed ID: 20182874
[TBL] [Abstract][Full Text] [Related]
15. Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53.
Kumai T; Ishibashi K; Oikawa K; Matsuda Y; Aoki N; Kimura S; Hayashi S; Kitada M; Harabuchi Y; Celis E; Kobayashi H
Cancer Immunol Immunother; 2014 May; 63(5):469-78. PubMed ID: 24633296
[TBL] [Abstract][Full Text] [Related]
16. Phase I dendritic cell p53 peptide vaccine for head and neck cancer.
Schuler PJ; Harasymczuk M; Visus C; Deleo A; Trivedi S; Lei Y; Argiris A; Gooding W; Butterfield LH; Whiteside TL; Ferris RL
Clin Cancer Res; 2014 May; 20(9):2433-44. PubMed ID: 24583792
[TBL] [Abstract][Full Text] [Related]
17. Blocking senescence and tolerogenic function of dendritic cells induced by γδ Treg cells enhances tumor-specific immunity for cancer immunotherapy.
Si F; Liu X; Tao Y; Zhang Y; Ma F; Hsueh EC; Puram SV; Peng G
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580332
[TBL] [Abstract][Full Text] [Related]
18. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine.
Liu JY; Wu Y; Zhang XS; Yang JL; Li HL; Mao YQ; Wang Y; Cheng X; Li YQ; Xia JC; Masucci M; Zeng YX
Cancer Immunol Immunother; 2007 Oct; 56(10):1597-604. PubMed ID: 17440723
[TBL] [Abstract][Full Text] [Related]
19. An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2.
Nabekura T; Nagasawa T; Nakauchi H; Onodera M
Cancer Immunol Immunother; 2008 May; 57(5):611-22. PubMed ID: 17786440
[TBL] [Abstract][Full Text] [Related]
20. Articulatin B chain induced dendritic cells maturation and driven type I T helper cells and cytotoxic T cells activation.
Lu TL; Sher YP; Chen HC; Cheng WC; Hsu LH; Lee CC
Life Sci; 2022 Aug; 302():120635. PubMed ID: 35569571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
